Publication date: Mar 23, 2020
To compare the prognostic value of imaging biomarkers derived from a quantitative analysis of baseline 18F-FDG-PET/CT in patients with mucosal melanoma (Muc-M) or cutaneous melanoma (Cut-M) treated with immune checkpoint inhibitors (ICIs).
In this retrospective monocentric study, we included 56 patients with non-resectable Muc-M (n?=?24) or Cut-M (n?=?32) who underwent baseline 18F-FDG-PET/CT before treatment with ICIs between 2011 and 2017. Parameters were extracted from (i) tumoral tissues: SUVmax, SUVmean, TMTV (total metabolic tumor volume), and TLG (total lesion glycolysis) and (ii) lymphoid tissues: BLR (bone marrow-to-liver SUVmax ratio) and SLR (spleen-to-liver SUVmax ratio). Association with survival and response was evaluated using Cox prediction models, Student’s t tests, and Spearman’s correlation respectively. p?
Seban, R.D., Moya-Plana, A., Antonios, L., Yeh, R., Marabelle, A., Deutsch, E., Schwartz, L.H., G’omez, R.G.H., Saenger, Y., Robert, C., Ammari, S., and Dercle, L. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. 26212. 2020 Eur J Nucl Med Mol Imaging.